Literature DB >> 19096558

Long-term Outcomes of Gamma Knife Stereotactic Radiosurgery of Vestibular Schwannomas.

Kang-Min Kim1, Chul-Kee Park, Hyun-Tai Chung, Sun Ha Paek, Hee-Won Jung, Dong Gyu Kim.   

Abstract

OBJECTIVE: Gamma Knife Stereotactic Radiosurgery (GK SRS) has become an important treatment modality for vestibular schwannomas. We evaluated the tumor control rate, patterns of tumor volume change and preservation of hearing following low-dose radiation for vestibular schwannomas in a homogeneous cohort group in which the mean marginal dose was 12 Gy.
METHODS: A total of 59 patients were enrolled in this study. All enrolled patients were followed-up for at least 5 years and the radiation dose was 11-13 Gy. Regular MRI, audiometry and clinical evaluations were done and tumor volumes were obtained from MRI using the OSIRIS program.
RESULTS: The tumor control rate was 97%. We were able to classify the patterns of change in tumor volume into three categories. Transient increases in tumor volume were detected in 29% of the patients and the maximum transient increase in tumor volume was identified at 6 to 30 months after GK SRS. The transient increases in tumor volume ranged from 121% to 188%. Hearing was preserved in 4 of the 12 patients who had serviceable hearing prior to treatment. There were no other complications associated with GK SRS.
CONCLUSION: Low-dose GK SRS was an effective and safe mode of treatment for vestibular schwannomas in comparison to the previously used high-dose GK SRS. Transient increases in tumor volume can be identified during the follow-up period after low-dose GK SRS for vestibular schwannomas. Physicians should be aware that these increases are not always indicative of treatment failure and that close observation is required following treatments. Unfortunately, a satisfactory hearing preservation rate was not achieved by reducing the radiation dose. It is thought that hearing preservation is a more sophisticated problem and further research is required.

Entities:  

Keywords:  Gamma knife; Long-term outcome; Low dose; Vestibular schwannomas

Year:  2007        PMID: 19096558      PMCID: PMC2588215          DOI: 10.3340/jkns.2007.42.4.286

Source DB:  PubMed          Journal:  J Korean Neurosurg Soc        ISSN: 1225-8245


  33 in total

1.  Reduced-dose radiosurgery for vestibular schwannomas.

Authors:  J H Petit; R S Hudes; T T Chen; H M Eisenberg; J M Simard; L S Chin
Journal:  Neurosurgery       Date:  2001-12       Impact factor: 4.654

2.  Stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of acoustic schwannomas: comparative observations of 125 patients treated at one institution.

Authors:  D W Andrews; O Suarez; H W Goldman; M B Downes; G Bednarz; B W Corn; M Werner-Wasik; J Rosenstock; W J Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-08-01       Impact factor: 7.038

3.  Cranial nerve preservation after radiosurgery of vestibular schwannomas.

Authors:  F Unger; C Walch; O Schröttner; S Eustacchio; B Sutter; G Pendl
Journal:  Acta Neurochir Suppl       Date:  2002

Review 4.  Optimal dose of stereotactic radiosurgery for acoustic neuromas: A systematic review.

Authors:  R S Weil; J M Cohen; I Portarena; M Brada
Journal:  Br J Neurosurg       Date:  2006-08       Impact factor: 1.596

5.  Gamma knife radiosurgery of acoustic neurinomas.

Authors:  A Bertalanffy; W Dietrich; M Aichholzer; R Brix; A Ertl; K Heimberger; K Kitz
Journal:  Acta Neurochir (Wien)       Date:  2001       Impact factor: 2.216

6.  [Changing radiological results, pitfalls and criteria of failure].

Authors:  C Delsanti; M Tamura; D Galanaud; J Régis
Journal:  Neurochirurgie       Date:  2004-06       Impact factor: 1.553

7.  Radiation exposure of normal temporal bone structures during stereotactically guided gamma knife surgery for vestibular schwannomas.

Authors:  Mark E Linskey; Peter A S Johnstone; Michael O'Leary; Steven Goetsch
Journal:  J Neurosurg       Date:  2003-04       Impact factor: 5.115

8.  Radiosurgery for acoustic neuromas: results of low-dose treatment.

Authors:  Yoshiyasu Iwai; Kazuhiro Yamanaka; Masato Shiotani; Taichi Uyama
Journal:  Neurosurgery       Date:  2003-08       Impact factor: 4.654

9.  Stereotactic radiosurgery in cases of acoustic neurinoma: further experiences.

Authors:  G Norén; J Arndt; T Hindmarsh
Journal:  Neurosurgery       Date:  1983-07       Impact factor: 4.654

10.  The efficacy of corticosteroids in restoring hearing in patients undergoing conservative management of acoustic neuromas.

Authors:  Anna Aronzon; Michael J Ruckenstein; Douglas C Bigelow
Journal:  Otol Neurotol       Date:  2003-05       Impact factor: 2.311

View more
  6 in total

1.  Small Vestibular Schwannomas: Does Surgery Remain a Viable Treatment Option?

Authors:  Amjad N Anaizi; Vincent V DiNapoli; Myles Pensak; Philip V Theodosopoulos
Journal:  J Neurol Surg B Skull Base       Date:  2015-10-08

2.  Gamma knife radiosurgery for trigeminal schwannoma: a 20-year experience with long-term treatment outcome.

Authors:  Jiwook Ryu; Sung Ho Lee; Seok Keun Choi; Young Jin Lim
Journal:  J Neurooncol       Date:  2018-06-21       Impact factor: 4.130

3.  Long-Term Outcomes of Fractionated Stereotactic Proton Therapy for Vestibular Schwannoma: A Case Series.

Authors:  Simeng Zhu; Ronny Rotondo; William M Mendenhall; Roi Dagan; Debbie Lewis; Soon Huh; Glenn Knox; Daryoush Tavaniepour; Sukhwinder Sandhu; Michael S Rutenberg
Journal:  Int J Part Ther       Date:  2018-07-26

4.  Cell Transplantation to Restore Lost Auditory Nerve Function is a Realistic Clinical Opportunity.

Authors:  Tetsuji Sekiya; Matthew C Holley
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

5.  A meta-analysis of treatment of vestibular schwannoma using Gamma Knife radiosurgery.

Authors:  Bartosz Rykaczewski; Miroslaw Zabek
Journal:  Contemp Oncol (Pozn)       Date:  2014-01-25

6.  Prediction of transient tumor enlargement using MRI tumor texture after radiosurgery on vestibular schwannoma.

Authors:  Patrick P J H Langenhuizen; Sander H P Sebregts; Svetlana Zinger; Sieger Leenstra; Jeroen B Verheul; Peter H N de With
Journal:  Med Phys       Date:  2020-02-18       Impact factor: 4.071

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.